Literature DB >> 761086

Differential serotonergic innervation of individual hypothalamic nuclei and other forebrain regions by the dorsal and median midbrain raphe nuclei.

L D van de Kar, S A Lorens.   

Abstract

Lesions in the midbrain median but not in the dorsal raphe nucleus significantly decreased the serotonin (5-HT) content of the hippocampus (61%), medial preoptic area (49%), suprachiasmatic nucleus (70%) and anterior hypothalamic area (60%). Electrolytic lesions restricted to either the median or dorsal raphe nucleus produced significant reductions in the 5-HT concentration of the caudate-putamen, anterolateral hypothalamic area (45%) and arcuate nucleus (48--58%). The fall in caudate-putamen 5-HT level was significantly greater after the dorsal (66%) than after the median (24%) raphe lesion. Neither lesion significantly affected the 5-HT content of the posterolateral hypothalamic area, the ventromedial hypothalamic nucleus or the dorsomedial hypothalamic nucleus. Thus, like their differential projections to the caudate-putamen and hippocampus, the mesencephalic dorsal and median raphe nuclei appear to innervate different preoptico-hypothalamic nuclei and areas. Whereas the median raphe nucleus seems to be the primary source of 5-HT fibers to the suprachiasmatic nucleus, anterior hypothalamic area and medial preoptic area, the 5-HT inputs to the anterolateral hypothalamic area and arcuate nucleus appear to derive from both the dorsal and median raphe nuclei.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 761086     DOI: 10.1016/0006-8993(79)90754-6

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  25 in total

Review 1.  A short history of the 5-HT2C receptor: from the choroid plexus to depression, obesity and addiction treatment.

Authors:  Jose M Palacios; Angel Pazos; Daniel Hoyer
Journal:  Psychopharmacology (Berl)       Date:  2017-03-07       Impact factor: 4.530

2.  Serotonin-specific lesions of the dorsal raphe disrupt maternal aggression and caregiving in postpartum rats.

Authors:  M Allie Holschbach; Erika M Vitale; Joseph S Lonstein
Journal:  Behav Brain Res       Date:  2018-04-10       Impact factor: 3.332

3.  Quantitative and ultrastructural study of ascending projections to the medial mammillary nucleus in the rat.

Authors:  T Hayakawa; K Zyo
Journal:  Anat Embryol (Berl)       Date:  1991

Review 4.  Mesencephalic and extramesencephalic dopaminergic systems in Parkinson's disease.

Authors:  Fanni F Geibl; Martin T Henrich; Wolfgang H Oertel
Journal:  J Neural Transm (Vienna)       Date:  2019-01-14       Impact factor: 3.575

5.  Circadian variation in sensitivity of suprachiasmatic and lateral geniculate neurones to 5-hydroxytryptamine in the rat.

Authors:  R Mason
Journal:  J Physiol       Date:  1986-08       Impact factor: 5.182

6.  Independent effects of cholinergic and serotonergic lesions on acetylcholine and serotonin release in the neocortex of the rat.

Authors:  A J Dekker; L J Thal
Journal:  Neurochem Res       Date:  1993-03       Impact factor: 3.996

7.  Daily variations in in vivo tryptophan hydroxylation and in the contents of serotonin and 5-hydroxyindoleacetic acid in discrete brain areas of the rat.

Authors:  L Poncet; L Denoroy; M Jouvet
Journal:  J Neural Transm Gen Sect       Date:  1993

8.  Substance P in the suprachiasmatic nucleus of the rat: an immunohistochemical and in situ hybridization study.

Authors:  J D Mikkelsen; P J Larsen
Journal:  Histochemistry       Date:  1993-07

9.  Effect of lesions of raphe nuclei on the activity of catecholaminergic and serotonergic neurones in various brain regions of the rat in vivo.

Authors:  H Rommelspacher; S Strauss
Journal:  J Neural Transm       Date:  1980       Impact factor: 3.575

10.  Towards a reconceptualization of striatal interactions between glutamatergic and dopaminergic neurotransmission and their contribution to the production of movements.

Authors:  Hélène N David
Journal:  Curr Neuropharmacol       Date:  2009-06       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.